Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome testing products and services, today announced that it has raised $21.4 million in a Series A funding round led by New Enterprise Associates (NEA). Other new and existing investors, including Windham Venture Partners and Nanjing Kaiyuan Growth Capital Investments, also participated in the financing.
PGDx was founded in 2010 by cancer researchers from Johns Hopkins University (JHU), who are pioneers in cancer genome sequencing and liquid biopsy technologies. Under the leadership of co-founders and JHU researchers Luis A. Diaz, MD, and Victor Velculescu, MD, PhD, the company has achieved consistent growth by successfully commercializing novel clinical and investigational products and services for researchers, drug developers, physicians and patients. PGDx’s service offerings for researchers are complemented by the clinical services it provides through its CLIA-certified laboratory.